RecruitingPhase 2NCT03418038
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Studying High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Thomas E Witzig, M.D.Mayo Clinic
- Intervention
- Ascorbic Acid(dietary_supplement)
- Enrollment
- 80 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2031
Study locations (4)
- Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
- Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03418038 on ClinicalTrials.gov